Almirall, S.A.

MCE ALM.MC

Almirall, S.A. Operating Income Margin for the year ending December 31, 2023: -0.59%

Almirall, S.A. Operating Income Margin is -0.59% for the year ending December 31, 2023, a -110.84% change year over year. Operating Income Ratio is the proportion of a company's operating income to its net sales, measuring the efficiency of its core business operations in generating profits.

Almirall, S.A. Operating Income Margin for the year ending December 31, 2022 was 5.43%, a -57.38% change year over year.
Almirall, S.A. Operating Income Margin for the year ending December 31, 2021 was 12.74%, a 122.88% change year over year.
Almirall, S.A. Operating Income Margin for the year ending December 31, 2020 was 5.72%, a -67.39% change year over year.
Almirall, S.A. Operating Income Margin for the year ending December 31, 2019 was 17.53%, a 52.51% change year over year.

Key data

Date	Operating Income Margin	EBT Margin	Net Income Margin	EBITDA Margin

MCE: ALM.MC

Almirall, S.A.

CEO	Mr. Carlos Gallardo Piqué
IPO Date	June 20, 2007
Location	Spain
Headquarters	Ronda Del General Miter, 151
Employees	1,904
Sector	Health Care
Industries Pharmaceuticals Biotechnology Cosmetics

Description

Almirall, S.A., a biopharmaceutical company, engages in the research, development, manufacture, and sale of skin-health related medicines in Europe, the United States, and internationally. The company offers its products for dermatological diseases comprising actinic keratosis, atopic dermatitis, androgenic alopecia, psoriasis, onychomycosis, oncodermatology, acne, and orphan indications, as well as for cardiovascular, musculo-skeletal, respiratory, and nervous system; alimentary tract and metabolism; antiinfectives for systemic use; genito urinary system and sex hormones; immunostimulants; and systematic hormonal preparations. Its products include Ilumetri, Solaraze, Actikerall, Ciclopoli, Skilarence, Aczone, Decoderm, Cordran Tape, Azelex, Klisyri, Tazorac, Seysara, Veltin, Almax, Ebastel, Sativex, Crestor, and Efficib/Tesavel. Almirall, S.A. has collaboration and partnership agreements with Tyris Therapeutics, BIOMAP, the University of Dundee, Kaken Pharmaceutical Co Ltd., Ichnos Sciences Inc., the University Carlos III Madrid and MEDINA Foundation, 23andMe, Inc., HitGen Ltd., WuXi Biologics, Eli Lilly and Company, and Athenex, Inc. The company was formerly known as Laboratorios Almirall, S.A. and changed its name to Almirall, S.A. in May 2009. Almirall, S.A. was founded in 1943 and is headquartered in Barcelona, Spain.

Key trends

Past 5 years